EX02 CAR-T Cells for Relapsed and Refractory Acute Myeloid Leukemia

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

August 1, 2026

Study Completion Date

September 1, 2029

Conditions
Acute Myeloid Leukemia (AML)CAR-T
Interventions
BIOLOGICAL

CAR-T Cell Injection

"Conditioning chemotherapy: Lymphodepletion regimen consisting of fludarabine 25 mg/m2/day and cyclophosphamide 250 mg/m2/day for 3 consecutive days, administered 48 hours before intraperitoneal infusion.~On the day of administration, premedication with 500mg of acetaminophen orally and 20mg of promethazine intramuscularly or intravenously (or other non-steroidal anti-inflammatory drugs and antihistamines) should be given 30 minutes before intraperitoneal infusion.~The therapeutic dose of CAR-T cells is defined as intravenous injection of 1.0E6 CAR-T cells/kg as the initial standard dosage."

Trial Locations (1)

230031

RECRUITING

The Second Affliated Hospital of Anhui Medical University, Hefei

All Listed Sponsors
collaborator

Zeno Therapeutics Pte. Ltd

UNKNOWN

lead

Zhimin Zhai

OTHER